MNKD

SEC source: 0001193125-26-237424 · ownership.xml · derivative · entry 2

Kay Sabrina · CIK 0001835895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,781

Underlying: Common Stock, $0.01 Par Value · 82,781 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F3 · kind: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.exercise_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

F3 · derivative.expiration_date: Restricted stock unit vested on May 20, 2026, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation.

SEC source: 0001193125-26-222311 · ownership.xml · nonDerivative · entry 2

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 808,008

F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.

F3 · price: The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.25 and $3.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-26-222310 · ownership.xml · nonDerivative · entry 2

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 826,299

F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 27, 2025.

F3 · price: The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.25 and $3.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-26-222312 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 992,224

F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.

SEC source: 0001193125-26-222311 · ownership.xml · nonDerivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 824,948

F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.

SEC source: 0001193125-26-222309 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,442,310

F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.

F2 · balance_after: Includes 1,356 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025.

SEC source: 0001193125-26-222310 · ownership.xml · nonDerivative · entry 1

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 829,332

F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022.

SEC source: 0001193125-26-178298 · ownership.xml · nonDerivative · entry 1

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,924

F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 15, 2024.

F2 · balance_after: Includes 2,337 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025.

SEC source: 0001193125-26-124726 · ownership.xml · derivative · entry 2

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,000

Underlying: Common Stock, $0.01 Par Value · 217,000 shares

Expires 2036-03-23

F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

SEC source: 0001193125-26-124726 · ownership.xml · derivative · entry 1

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,000

Underlying: Common Stock, $0.01 Par Value · 221,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0001193125-26-124725 · ownership.xml · derivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 782,000

Underlying: Common Stock, $0.01 Par Value · 782,000 shares

Expires 2036-03-23

F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

SEC source: 0001193125-26-124725 · ownership.xml · derivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 796,000

Underlying: Common Stock, $0.01 Par Value · 796,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0001193125-26-124724 · ownership.xml · derivative · entry 2

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,000

Underlying: Common Stock, $0.01 Par Value · 217,000 shares

Expires 2036-03-23

F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

SEC source: 0001193125-26-124724 · ownership.xml · derivative · entry 1

Singh Sanjay R · CIK 0001953423 · EVP Technical Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,000

Underlying: Common Stock, $0.01 Par Value · 221,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0001193125-26-124722 · ownership.xml · derivative · entry 2

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,000

Underlying: Common Stock, $0.01 Par Value · 217,000 shares

Expires 2036-03-23

F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

SEC source: 0001193125-26-124722 · ownership.xml · derivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,000

Underlying: Common Stock, $0.01 Par Value · 221,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0001193125-26-124723 · ownership.xml · derivative · entry 2

Ahuja Ajay · CIK 0002090878 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,000

Underlying: Common Stock, $0.01 Par Value · 217,000 shares

Expires 2036-03-23

F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

SEC source: 0001193125-26-124723 · ownership.xml · derivative · entry 1

Ahuja Ajay · CIK 0002090878 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,000

Underlying: Common Stock, $0.01 Par Value · 221,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0001193125-26-124721 · ownership.xml · derivative · entry 2

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,000

Underlying: Common Stock, $0.01 Par Value · 217,000 shares

Expires 2036-03-23

F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.

SEC source: 0001193125-26-124721 · ownership.xml · derivative · entry 1

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 221,000

Underlying: Common Stock, $0.01 Par Value · 221,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

SEC source: 0001193125-26-100839 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,575,911

F1 · price: The weighted average purchase price of the reported transaction was $2.59 based on a range of prices between $2.58 and $2.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001193125-26-086379 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,475,911

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on March 1, 2026.

SEC source: 0001193125-26-086376 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,297

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on March 1, 2026.

SEC source: 0001193125-26-089613 · ownership.xml · nonDerivative · entry 1

Shannon James Samuel · CIK 0001485417 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,635

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on March 1, 2026.

SEC source: 0001193125-26-089612 · ownership.xml · nonDerivative · entry 1

HOOPER ANTHONY C · CIK 0001277244 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,153

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on March 1, 2026.

SEC source: 0001193125-26-089611 · ownership.xml · nonDerivative · entry 1

Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 348,854

F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on March 1, 2026.

SEC source: 0001193125-26-086379 · ownership.xml · derivative · entry 4

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,525

Underlying: Stock Options · 37,525 shares

Expires 2027-05-25

F4 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-086379 · ownership.xml · derivative · entry 3

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,750

Underlying: Stock Options · 57,750 shares

Expires 2027-05-29

F3 · kind: On May 29, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-086379 · ownership.xml · derivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Stock Options · 50,000 shares

Expires 2026-05-19

F2 · kind: On May 19, 2016, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-086378 · ownership.xml · derivative · entry 1

Binder Steven B. · CIK 0001712601 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,025

Underlying: Stock Options · 45,025 shares

Expires 2027-08-23

F1 · kind: On August 24, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-086377 · ownership.xml · derivative · entry 2

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,525

Underlying: Stock Options · 37,525 shares

Expires 2027-05-25

F2 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-086377 · ownership.xml · derivative · entry 1

Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Stock Options · 20,000 shares

Expires 2026-05-19

F1 · kind: On May 19, 2016, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-086376 · ownership.xml · derivative · entry 3

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,143

Underlying: Stock Options · 28,143 shares

Expires 2027-05-25

F3 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-086376 · ownership.xml · derivative · entry 2

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Stock Options · 20,000 shares

Expires 2027-02-15

F2 · kind: On February 16, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option.

SEC source: 0001193125-26-009297 · ownership.xml · nonDerivative · entry 1

Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 985,007

F1 · kind: Transaction occured pursuant to Rule 10B5-1 Plan established June 17, 2025.

SEC source: 0001193125-25-335655 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,460,621

F1 · kind: Shares gifted as a charitable donation.

SEC source: 0001193125-25-327227 · ownership.xml · derivative · entry 4

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 50,000 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-327227 · ownership.xml · derivative · entry 3

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 15,804 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-327227 · ownership.xml · nonDerivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,504,792

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.

F2 · price: The weighted average sales price of the reported transaction was $6.01 based on a range of prices between $6.00 and $6.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001193125-25-327227 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,570,596

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-321366 · ownership.xml · derivative · entry 7

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,804

Underlying: Common Stock, $0.01 Par Value · 21,310 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 4

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,504,792

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.

SEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 3

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,526,102

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-321366 · ownership.xml · derivative · entry 6

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,114

Underlying: Common Stock, $0.01 Par Value · 12,886 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-321366 · ownership.xml · derivative · entry 5

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 7,920 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,504,792

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.

SEC source: 0001193125-25-321366 · ownership.xml · nonDerivative · entry 1

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,525,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-308350 · ownership.xml · derivative · entry 4

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,920

Underlying: Common Stock, $0.01 Par Value · 42,080 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-308350 · ownership.xml · derivative · entry 3

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock, $0.01 Par Value · 65,840 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-308350 · ownership.xml · nonDerivative · entry 2

Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,504,792

F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 8, 2025.

F2 · price: The weighted average sales price of the reported transaction was $5.57 based on a range of prices between $5.50 and $5.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.